Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,886.24
(
1.02%
)
US TECH 100
24,816.80
(
0.49%
)
Dow Jones
48,218.25
(
0.63%
)
Brent Oil
95.74
(
0.28%
)
Bitcoin
74,778.34
(
0.38%
)
News Focus
News Focus
Post# of 257403
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122865
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 238083

Wednesday, 05/19/2021 6:40:21 PM

Wednesday, May 19, 2021 6:40:21 PM

Post# of 257403
More takes on BMY’s Relatlimab data in 1L-melanoma:

https://finance.yahoo.com/news/bristol-myers-immunotherapy-combo-better-210005484.html (Reuters)

https://www.evaluate.com/vantage/articles/events/conferences/asco-2021-bristols-lag3-case-replacement-yervoy (Evaluate Vantage)

https://www.biopharmadive.com/news/bristol-myers-details-data-for-closely-watched-cancer-immunotherapy/600386/ (BiopharmaDrive)

https://twitter.com/DewDiligence/status/1395141087413538822 (my abbreviated take)

BMY is +1% in AH trading. The bump would presumably be higher if the positive PFS outcome had not been announced two months ago (#msg-162784750).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today